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The major cause of death in humans is directly related to vascular diseases[1]. The development of 
vascular pathology is often coupled to dramatic alterations of the extracellular matrix (ECM), which 
provides critical support for vascular tissue as a scaffold for maintaining the organization of vascular cells 
into blood vessels, for blood vessel stabilization, morphogenesis, and for cell proliferation, migration, and 
survival[2]. The ECM constitutes a complex milieu of macromolecules that influence, throughout specific 
interactions, the activities of the cells, including cell migration and proliferation. Hyaluronan (HA) is an 
important component of the ECM that has generated increasing interest within the scientific community 
due to its multitude of functions. HA is a linear polymer belonging to the family of glycosaminoglycans 
(GAGs), which comprises the major fraction of carbohydrates in ECM[3] . Even though HA is not 
covalently bound to a protein core as the other GAGs that form proteoglycans, it can interact with several 
proteinaceous molecules (hyaloadherins)[4]. HA is a substrate onto which other proteins could bind, 
including proteoglycans that can assemble, forming a complex network in ECM. This aggregation 
maintains the physical form and the biochemical properties of tissues, underlining that HA has not only a 
structural function, but it also is a regulator of cellular behavior[5]. 
Cell motility is critical in several pathologies and in vascular biology, human aortic smooth muscle 
cell (AoSMC) migration represents a crucial point in the onset of pathology[6]. In normal vessels, 
AoSMCs are mainly located within the tunica media of blood vessels in a contractile state, expressing 
specific genes essential for cell function, such as regulation of vessel tone and blood pressure[7]. A large 
body of scientific evidence supports the concept that one of the most precocious events during the onset 
of arteriosclerosis or restenosis in vessels is the AoSMC migration towards the intima layer. In fact, under 
pathological conditions, such as vessel injury or arteriosclerotic plaque development, AoSMCs become 
exposed to certain growth factors, inflammatory cytokines, and other circulating components that induce 
a transformation from the contractile to a synthetic state[8]. Only in this synthetic behavior do the 
AoSMCs acquire the ability to proliferate, migrate, and accumulate within the intimal layer of arteries 




under the influence of chemotaxis-inducing growth factors. During the migration, AoSMCs have been 
shown to digest major extracellular barriers, such as basal membranes, interstitial collagens, and 
proteoglycans[9].  
It is well known that the onset of vascular pathologies increases with aging and, interestingly, even 
AoSMCs change their gene expression pattern and their ECM composition during aging, exerting direct 
effects on various cellular events and cell migration[10]. In fact, a role for HA during AoSMC migration 
was recently established and, therefore, its possible involvement in vascular pathology[10]. In recent 
papers, it was demonstrated that the AoSMCs produce large amounts of HA[11] and that the ECM 
strongly influences cell migration[12]. The data obtained on HA synthesis in AoSMCs during aging 
confirm the idea that the ECM modification can alter cell migration. In vitro, aged cells produced more 
HA and its receptor CD44 on the cell membrane. In this in vitro aging model, primary AoSMCs were 
cultured for several population doublings and cells with a high number of mitosis were considered aged. 
The robustness of this study was achieved by measuring several markers of senescence (as P16 and 
galactosidase activity) and verifying the phenotype of cells during the senescence process in vitro. The 
role of HA and its receptor CD44 on AoSMC motility was demonstrated as blocking CD44 activity. In 
fact, experiments that carried out blocking the receptor or its signal transmission (the ERK1/2 
phosphorylation) abolished the HA effect on cell motility[10]. Moreover, modifying the HA content in 
the cells by adding HA of different molecular size to the cell culture at different concentrations increased 
cell motility. In fact, the HA size is critical for this modulation as low-molecular-weight HA does not 
show the same effect observed using high-molecular-weight HA. However, as other pathways involving 
VCAM and ICAM proteins could potentially control the migratory capability of AoSMCs, the 
involvement of VCAM and ICAM throughout the evaluation of the expression in young and aged 
AoSMCs of these molecules was ruled out. Therefore, HA, through CD44 and ERK phosphorylation, was 
shown to control AoSMC migration. These experiments demonstrate that the interaction of HA and cell 
receptor CD44 is critical in the AoSMC motility, highlighting the role of the microenvironment in cell 
migration[10,11,12].  
In the literature, it was shown that the amount of HA increases during the early arteriosclerotic 
process, indicating that this polymer could play a critical role in this process[13]. In the model of aged 
AoSMCs, it was demonstrated that HA production, as well as the synthesis of its receptor CD44[9], 
increased and that the accumulation of HA in AoSMCs is specific, as the other GAGs did not increase 
their amount during in vitro aging. The analysis of AoSMC cell motility in aged cells demonstrated that 
the increased HA induces a higher motility and that this phenomenon was CD44 dependent. It is known 
that CD44 promotes arteriosclerosis[14] and that AoSMC migration during aging depends on HA, CD44, 
and the phosphorylation of MAP kinase ERK 1/2. Because CD44 signaling can modify the activity of the 
extracellular signal-related kinase ERK 1/2[15], the high CD44 expression in aged cells could mediate 
higher levels of phosphorylated ERK1/2 protein. Hence, CD44 and RHAMM (another HA receptor) can 
influence AoSMC behavior[16,17]; the expression of CD44 was significantly increased in both aged 
AoSMCs as well as in adult human aorta RNA[9], supporting the idea that the in vitro cell model of 
AoSMCs resembles an in vivo condition[10]. It was reported that CD44-modulating cell motility could 
play a role in several pathologies[18].  
Considering the role of HA in the AoSMC migration, it may be reasonable to assume that the 
inhibition of HA synthesis in vivo in the vascular tissue may contribute to reduction of the cell migration. 
4-Metyllumbelliferone (4-MU), a well-known HA synthesis inhibitor[19], could be considered as a 
candidate for drug-eluting stents in order to prevent cell migration and, in final extent, the vessel 
restenosis. Moreover, other approaches are available in therapy to inhibit restenosis, as drug-eluting stents 
that release sirolimus or paclitaxel that arrest SMC cell cycle and migration[20]. Recently, sirolimus has 
been discovered to inhibit vascular SMC HA secretion[21] and the role of hyaluronan synthases 
expression was related to the monocyte adhesion in SMC[22]. By reducing HA synthesis and therefore 
the AoSMC motility, 4-MU could represent a new molecule with additional beneficial pharmacological 
effects in vivo. 
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